AbbVie seeks FDA OK for triple direct-acting HCV antiviral
This article was originally published in Scrip
AbbVie revealed on 22 April it had submitted a new drug application (NDA) to the FDA for the company's triple direct-acting antiviral (DAA) combination regimen – ABT-450/r, a protease inhibitor and ritonavir; ombitasvir (ABT-267), a NS5A inhibitor; and dasabuvir (ABT-333), a non-nucleoside polymerase inhibitor – with or without ribavirin for patients with hepatitis C virus (HCV) genotype 1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.